An interventional study of Sending of screening summon. in Cervical Cancer, Uterine Cervical Neoplasm and Uterine Neoplasms, sponsored by Karolinska Institutet. Recruiting at 6 sites in Sweden. Open to female participants aged 33 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-01-14.
Sponsored by Karolinska Institutet · Not applicable, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 33 studies in Uterine Cervical Neoplasms with a site in Sweden — 9 open to participants now, 13 under way, 2 of them phase 3. Uterine Cervical Neoplasms · Sweden.
Among the 33 studies in Uterine Cervical Neoplasms with a site in Sweden, this one is the 4th largest by planned enrollment of the 25 interventional ones that give a count, is one of 4 that started in 2019, is one of 9 with no phase, reaches primary completion later than 8 of the 12 other live ones, and was the 15th registered.
2,369 studies on the registry are indexed under Uterine Cervical Neoplasms; 678 are open to participants now.
Browse Uterine Cervical Neoplasms studies →9 of the 33 studies in Uterine Cervical Neoplasms with a site in Sweden are open now. Recruiting first, the newest first:
Karolinska University Hospital · Sites in Sweden
Ages 18+
Merck Sharp & Dohme LLC · Sites in Sweden, United States, Argentina and 26 more countries
Ages 18+ · Women only
Region Västerbotten · Sites in Sweden
Ages 18+ · Women only
Miriam Elfström · Sites in Sweden
Ages 22–27 · Women only
Universitaire Ziekenhuizen KU Leuven · Sites in Sweden, Belgium, Czechia and 1 more country
Ages 18+ · Women only
A study can be open while its sites in Sweden have not opened yet or have stopped. Only those recruiting at a site in Sweden →
Of the 476 Uterine Cervical Neoplasms studies recruiting now, 245 (51%) set no upper age limit and 191 (40%) stop at 75 or younger; 20 take children under 18; 68 take healthy volunteers.
This study: 33 Years to 75 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
33 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 3 · Phase 3 9 · Phase 4 1
First in 1996; this study’s year is marked. 4 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 20,000 is above the median of 100 across 1,740 interventional studies indexed under Uterine Cervical Neoplasms.
Median enrollment 744 across the 25 interventional studies, 180 across the 8 observational. Of the 19 that completed or were terminated, 6 (32%) have results posted.
This tab as a report to print or save as PDF → With an account.
11 of 33 have an industry lead sponsor. The 10 most frequent:
Karolinska Institutet is the lead sponsor of 1,150 studies on the registry; 276 are open to participants now.
Karolinska Institutet has 8 studies filed under Uterine Cervical Neoplasms — fewer than ten, so there is no comparison to draw.
2 of the studies in Uterine Cervical Neoplasms with a site in Sweden that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03719547Karolinska InstitutetRobot-assisted Approach to Cervical Cancer | 2027-03-30 |
| NCT06639191Karolinska University Hospital[177Lu]Lu-AKIR001 First-in-human Study | 2027-11-01 |
Add all 2 to your calendar (.ics) → With an account.
Among the 33 studies in Uterine Cervical Neoplasms with a site in Sweden, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Prevention of cervical cancer with cervical screening is one of the most successful screening activities in medicine. In Sweden, screening was implemented in the 1960s and has since prevented tens of thousands of women from having cervical cancer. Individual invitations to screening result in increased attendance therefore evaluating strategies for reaching women through invitations is particularly valuable. Women who regularly attend screening following an invitation reduce their risk of cervical cancer by as much as 90%. Of the women who are diagnosed with cervical cancer (about 550 women per year in Sweden), as many as 38% did not participate in the screening. Invitations for screening are sent to the entire population in Sweden aged 23-70. The current coverage of screening is 82.9%, which represents the proportion of women ages 23-70 who attend according to recommendations. In addition, many women are sporadic attenders who reduce their risk for cancer somewhat. The highest cancer risk is seen among those women who have never participated as well as women who have had a history of precancerous lesions or HPV infection but have not been followed-up. Cervical cancer is the first form of cancer for which there are approved molecular screening tests (HPV test). Unlike the older screening method (cytology), self-collected samples can be analyzed for HPV (the analysis method is so sensitive that it does not matter if the sample is not optimally taken).
Invitations and reminders about cervical screening are sent by letter to the woman's home address (about 3 million letters per year in Sweden). This strategy results in a waste of resources and has a negative environmental impact. Regarding reminders, we have seen in previous research that the effect is not optimal. When sending a physical reminder letter to women who have not participated in more than 10 years (current routine), only 2% of the women invited came for sampling. Reminders with SMS are now standard for many businesses in society, such as car testing or dental appointments. It is inexpensive, saves the environment and there are studies that suggest it is more effective than sending physical letters. In this study, we intend to investigate whether SMS reminders, electronic letters, and physical letters for screening lead to increased participation and thus to a higher proportion of detected, treatable precursors of cervical cancer compared to before.
Non-participation in the cervical screening program and sub-optimal follow-up after abnormalities or infection with a highly oncogenic HPV type detected in screening are the main risk factors for cervical cancer. Given this, It is important to reduce barriers to screening and facilitate participation in the screening program of cervical cancer. Offering self-sampling kits for human papillomavirus (HPV) testing has been examined in several research studies as a way to reach women who have not responded to screening invitations. Women who have been lost to follow-up can also be reached with self-sampling.
The purpose of this study is to investigate whether SMS reminders and electronic letters for screening attendance will increase participation compared to the current method where reminders are sent out with physical letters. In this study, women a with high risk of developing cervical cancer, due to not fully participating in screening or being followed up optimally, will be invited. Women are identified through registry linkages annually that examine screening history and status using a risk algorithm. Women receive an SMS or an electronic letter with an offer to request a self-sampling kit via the internet. Women with a higher risk for cervical cancer can be offered a self-sampling kit sent directly to their home address. The self-sampling kit comes with an instruction on how to take the sample and a postage-free answer envelope.
Submitted samples are analyzed with an approved and accredited method (Cobas 4800, Roche) that analyzes for HPV 16, HPV18 and other oncogenic HPV types. As the screening program changed the accredited HPV test in 2022 (to BD Onclarity), that test will be used from the timepoint of the change and onwards.
In the pilot of the study, follow-up is defined as follows:
The study has the usual level of confidence (p \<0.05 two-sided) and statistical power (80%) the ability to demonstrate an increase of participation by 3 times or more.
The protocol was piloted in the Region of Skåne in 2019 and then rolled out nationally in 2020.
The study is rolled out nationally with annual linkages to identify women with an excess risk for cervical cancer and an adaptive approach to reaching women with SMS, electronic letters, and physically letters with direct delivery of HPV self-sampling kits or an option to order a self-sampling kid (depending on risk). The study is coordinated centrally and each region has a contact person to whom women who need follow-up are referred.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
An invitation to order a HPV self sampling test through an online application will be sent by SMS or electronic letter.
Other: Sending of screening summon.
2019-2021 - A Cobas PCR Female swab sample packet will be sent. Response rates (participation) will be measured. 2022 and onwards - A FLOQSwab and corresponding sample tube for analysis on the BD COR platform will be sent.
Also known as: Response to screening summon.
Proportion of women responding to summon
Participation rate in screening after summons.
Time frame: Measured from the date of the summons until 12 months after the summons
Number of positive screens
Screening test results
Time frame: Measured from the date of the summons until 12 months after the summons
Rate of precursors of cancer
Cytologically and histopathologically confirmed percursors of cervical cancer.
Time frame: Measured from the date of the summons until 12 months after the summons
Rate of cancer
Histopathologically confirmed cervical cancers.
Time frame: Measured from the date of the summons until 12 months after the summons
Plan to share: No
Started Aug 2019 (actual). Primary completion is estimated for Jun 2030, 129 months after the start.
Of 446 non-industry interventional studies with no phase under Uterine Cervical Neoplasms, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 71. This study's planned 129 months is above that.
Counting every sponsor, half of 462 studies reached it within 33 months; a quarter within 15 and three quarters within 71.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.